et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.07.018 (Peer Reviewed)
Small retrospective database analysis of 36 patients receiving HCQ not showing significant differences. Confounding by indication is likely.
Kalligeros et al., 8/5/2020, retrospective, USA, North America, peer-reviewed, 13 authors.
risk of death, 67.0% higher, RR 1.67, p = 0.57, treatment 36, control 72.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.